AngioDynamics
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 8 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.1 percentage points.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 92.03% -1.10pp
- Institutions
- 210 +8
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 31 buys · 19 sells
| Name | Role | Stake |
|---|---|---|
| James Clemmer | Former Chief Executive Officer | 1.20% |
| Howard Donnelly | Independent Non-Executive Chairperson | 0.43% |
| Wesley Johnson | Independent Director | 0.36% |
| Stephen Trowbridge | Chief Financial Officer | 0.32% |
| Jan Reed | Independent Director | 0.28% |
| Eileen Auen | Independent Director | 0.28% |
| Karen Licitra | Independent Director | 0.24% |
| Michael Tarnoff | Independent Director | 0.23% |
| Laura Piccinini | Senior VP & GM of International | 0.20% |
| Lorinda Burgess | Independent Director | 0.16% |
| Chad Campbell | Senior VP and GM of Oncology & Interventional Devices | 0.15% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-01 | Eric Honroth | Chief Executive Officer | Other Acquisition | +101,193 | -- |
| 2026-11-01 | Eric Honroth | Chief Executive Officer | Other Derivative Acquisition | +62,928 | -- |
| 2026-10-28 | Stephen Trowbridge | Chief Financial Officer | Open Market Disposition | -25,335 | $12.17–12.27 |
| 2026-07-29 | Warren Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | Open Market Disposition | -23,370 | $14.72 |
| 2026-07-21 | Warren Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | Derivative Exercise and Sale | -1,671 | $13.82 |
| 2026-07-21 | Warren Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | Derivative Exercise and Retained | +4,023 | -- |
| 2026-07-21 | James Clemmer | Former Chief Executive Officer | Derivative Exercise and Sale | -26,728 | $13.82 |
| 2026-07-21 | James Clemmer | Former Chief Executive Officer | Derivative Exercise and Retained | +25,630 | -- |
| 2026-07-21 | Stephen Trowbridge | Chief Financial Officer | Derivative Exercise and Sale | -8,319 | $13.82 |
| 2026-07-21 | Stephen Trowbridge | Chief Financial Officer | Derivative Exercise and Retained | +7,977 | -- |
| 2026-07-21 | Laura Piccinini | Senior VP and GM of Cardiovascular & International | Derivative Exercise and Sale | -4,506 | $13.82 |
| 2026-07-21 | Laura Piccinini | Senior VP and GM of Cardiovascular & International | Derivative Exercise and Retained | +3,541 | -- |
| 2026-07-21 | Chad Campbell | Senior VP and GM of Oncology & Interventional Devices | Derivative Exercise and Sale | -2,330 | $13.82 |
| 2026-07-21 | Chad Campbell | Senior VP and GM of Oncology & Interventional Devices | Derivative Exercise and Retained | +4,136 | -- |
| 2026-07-19 | Warren Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain | Sale to Issuer | -3,777 | $13.51–14.14 |
| 2026-07-19 | James Clemmer | Former Chief Executive Officer | Sale to Issuer | -45,711 | $13.51–14.14 |
| 2026-07-19 | Stephen Trowbridge | Chief Financial Officer | Sale to Issuer | -12,067 | $13.51–14.14 |
| 2026-07-19 | Laura Piccinini | Senior VP and GM of Cardiovascular & International | Sale to Issuer | -8,228 | $13.51–14.14 |
| 2026-07-19 | Chad Campbell | Senior VP and GM of Oncology & Interventional Devices | Sale to Issuer | -3,838 | $13.51–14.14 |
| 2026-07-15 | Lawrence Weiss | Chief Legal Officer | Sale to Issuer | -2,267 | $14.14 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:01:15 · For reference only, not investment advice and not tailored to your situation.
AngioDynamics discussion 0 comments